The present teachings are directed at 1,1-di substituted alkene monomers (e.g., methylene beta-ketoester monomers), methods for producing the same, polymerizable compositions including a methylene beta-ketoester monomer, and polymers, compositions and products formed therefrom. The monomer preferably is a high purity monomer. In the method for producing the methylene beta-ketoesters of the invention, a beta-ketoester may be reacted with a source of formaldehyde. The methylene beta-ketoester monomers may be used in monomer-based products (e.g., inks, adhesives, coatings, sealants or reactive molding) and polymer-based products (e.g., fibers, films, sheets, medical polymers, composite polymers and surfactants).

Described herein are labeling agents, specifically [.sup.11C]fluoroform, [.sup.11C]difluoromethane, [.sup.11C]fluoromethyl iodide, [.sup.11C]fluoromethyl bromide, [.sup.11C]fluoromethyl chloride, [.sup.11C]fluoromethyl trifluoromethansulfonate, [.sup.11C]difluoromethyl iodide, [.sup.11C]difluoromethyl bromide, [.sup.11C]difluoromethyl chloride, [.sup.11C]difluoromethyl trifluoromethansulfonate, [.sup.11C]trifluoromethyl iodide, [.sup.11C]trifluoromethyl bromide, [.sup.11C]trifluoromethyl chloride, [.sup.11C]trifluoromethyl trifluoromethansulfonate, [.sup.18F]fluoroform, [.sup.18F]difluoromethane, [.sup.18F]difluoromethyl bromide or [.sup.18F]trifluoromethyl bromide. Also included are methods of labeling precursors to provide labeled fluoroalkanes and imaging methods.

Described herein are labeling agents, specifically [.sup.11C]fluoroform, [.sup.11C]difluoromethane, [.sup.11C]fluoromethyl iodide, [.sup.11C]fluoromethyl bromide, [.sup.11C]fluoromethyl chloride, [.sup.11C]fluoromethyl trifluoromethansulfonate, [.sup.11C]difluoromethyl iodide, [.sup.11C]difluoromethyl bromide, [.sup.11C]difluoromethyl chloride, [.sup.11C]difluoromethyl trifluoromethansulfonate, [.sup.11C]trifluoromethyl iodide, [.sup.11C]trifluoromethyl bromide, [.sup.11C]trifluoromethyl chloride, [.sup.11C]trifluoromethyl trifluoromethansulfonate, [.sup.18F]fluoroform, [.sup.18F]difluoromethane, [.sup.18F]difluoromethyl bromide or [.sup.18F]trifluoromethyl bromide. Also included are methods of labeling precursors to provide labeled fluoroalkanes and imaging methods.

The present disclosure provides processes for the preparation of a compound of formula:

##STR00001##

which is useful as an antiviral agent. The disclosure also provides compounds that are synthetic intermediates.

The present invention relates to a process for preparing indacaterol or salts thereof. The process comprises of forming compound of Formula 1 by reacting compound of Formula 2 and compound of Formula 3 in the presence of a solvent to Form compound of Formula 4, which on removal of the protecting groups forms compound of Formula 1.

The present invention relates to a process for preparing indacaterol or salts thereof. The process comprises of forming compound of Formula 1 by reacting compound of Formula 2 and compound of Formula 3 in the presence of a solvent to Form compound of Formula 4, which on removal of the protecting groups forms compound of Formula 1.

Disclosed are compounds which are nuclear receptor modulators that can act as antagonists to the androgen receptor, for example, a compound of Formula I:

##STR00001##

wherein R.sub.1 to R.sub.5 and X.sub.1 to X.sub.5 are as described herein, as well as pharmaceutically acceptable salts, solvates, and stereoisomers thereof. Pharmaceutical compositions comprising such compounds, as well as methods of use, and treatment for cancers, including prostate cancers, other nuclear receptor mediated cancers, and other conditions, are also disclosed.

Disclosed are compounds which are nuclear receptor modulators that can act as antagonists to the androgen receptor, for example, a compound of Formula I:

##STR00001##

wherein R.sub.1 to R.sub.5 and X.sub.1 to X.sub.5 are as described herein, as well as pharmaceutically acceptable salts, solvates, and stereoisomers thereof. Pharmaceutical compositions comprising such compounds, as well as methods of use, and treatment for cancers, including prostate cancers, other nuclear receptor mediated cancers, and other conditions, are also disclosed.

Methods of synthesis of hypervalent iodine reagents and methods for oxidation of organic compounds are disclosed.

Methods of synthesis of hypervalent iodine reagents and methods for oxidation of organic compounds are disclosed.